PHGDH, phosphoglycerate dehydrogenase, 26227

N. diseases: 288; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.070 Biomarker phenotype BEFREE 3-Phosphoglycerate dehydrogenase (PHGDH) catalyzes the first rate-limiting step for the synthesis of glucose-derived serine by converting 3-phosphoglycerate (3-PG) to phosphohydroxypyruvate (p-Pyr), which has been reported to associate with tumorigenesis in many cancers. 31112178 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.070 Biomarker phenotype BEFREE Mechanistically, knockdown of PHGDH inhibited cell proliferation and tumorigenesis through disrupting the cell-cell tight junctions and the related proteins expression. 30744688 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.070 Biomarker phenotype BEFREE Increased activity of the serine biosynthetic pathway through the enzyme phosphoglycerate dehydrogenase (PHGDH) contributes to tumorigenesis. 28042046 2017
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.070 Biomarker phenotype BEFREE Silencing PHGDH resulted in inhibition of tumorigenesis in vivo. 25719555 2015
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.070 Biomarker phenotype BEFREE Phosphoglycerate dehydrogenase is likely to be associated with tumorigenesis and may be a potential prognostic marker for CIN progression. 25205602 2015
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.070 Biomarker phenotype BEFREE Our data identified PHGDH as a potential prognostic marker of glial brain tumors and identified a non-metabolic role for PHGDH in glioma tumorigenesis, providing a novel angle of targeting the PHGDH-FOXM1 axis in future brain tumor therapy. 23229761 2013
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.070 Biomarker phenotype BEFREE Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. 21804546 2011